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Yeast Prions and Their Minireview
Prion-Forming Domain
The focus of research on yeast prions is now moving
to exploit this established and highly tractable model
system to elucidate the molecular basis of prion conver-
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Canterbury, Kent, CT2 7NJ sion and to extrapolate these findings to mammalian
prions. This of course raises the question of whetherUnited Kingdom
such extrapolation is valid.
Yeast and Mammalian Prion Conversion:
A Common Mechanism?Over a period of some 25 years the genetic analysis of
There is no direct evidence that the mechanism of estab-two completely unrelated mutants of the yeast Saccha-
lishment and transmission of the prion state of Sup35promyces cerevisiae posed a considerable dilemma to
and Ure2p parallels the mechanism of mammalian PrPyeast researchers. The two mutants in question, the
infectivity. Unlike Sup35p and Ure2p, PrP is not a cyto-[PSI1] mutant (which modifies the efficiency of nonsense
plasmic protein, but rather is a GPI-anchored glycopro-suppression) and the [URE3] mutant (which shows an
tein that transits through the secretory pathway ulti-alteration in nitrogen metabolism), failed to behave ac-
mately emerging on the cell surface where it becomescording to Mendel's laws. Non-Mendelian inheritance
attached to the plasma membrane via the GPI anchorin yeast of itself was not a surprising discovery. What
(Prusiner, 1999). Formation of the infectious prion formwas surprising was that no underlying cytoplasmically
of PrP (PrPSc) occurs after it subsequently transitslocated nucleic acid determinant could be assigned to
through the plasma membrane into a subcellular com-either mutant, prompting a wide-ranging debate about
partment; the formation of PrPSc therefore occurs in athe nature of the underlying genetic determinant(s) (re-
very different molecular and ionic environment to thatviewed in Cox et al., 1988).
in which the yeast prions reside. This raises the questionThe realization in 1994 that the unusual genetic behav-
of whether there can be any commonality of ªcofactorºior of both the [PSI1] and [URE3] mutants could be
requirements in yeast and mammalian prion conversion.explained by the prion-like behavior of two previously
Although the cytoplasmically located molecular chap-identified cellular proteins (Wickner, 1994) provided a
erone Hsp104 is essential for the formation and mainte-satisfying solution to the conundrum of how stable phe-
nance of the prion form of Sup35p in yeast (Chernoff etnotypic traits in yeast can be inherited in a non-Mende-
al., 1995), Hsp104 is not implicated in PrPSc formation.lian fashion yet have no apparent nucleic acid determi-
nant. By direct analogy with the well-studied behavior No mammalian Hsp104 homolog has been reported nor
would it be expected to be found in the subcellularof the mammalian prion protein PrP (Prusiner, 1999), the
proposed protein-based non-Mendelian inheritance of compartment to which PrP is delivered. In fact, no re-
quirement for a protein cofactor in PrPSc formation has[PSI1] and [URE3] would arise as a consequence of a
self-perpetuating change, most likely in conformation, been directly demonstrated. The recent demonstration
by Ma and Lindquist (1999) that mouse PrP expressedof a cellular protein. This in turn would result in the
partial (or complete) functional inactivation of the protein in the yeast cytoplasm acquires the biochemical charac-
teristics of PrPScÐincreased resistance to proteinase Kas a consequence of its ultimate aggregation leading
to an apparent loss-of-function phenotype. The self- digestion and detergent insolubilityÐimplies that the
glycosylation status of PrP and oxidative-reductive bal-propagating prion ªseeds,º which may not necessarily
be the aggregates leading to the [PSI1] or [URE3] pheno- ances may be two important parameters in defining the
conformation of PrP. Neither parameter is likely to betypes, would be inherited both mitotically and meioti-
cally through the cytoplasm. In the presence of these important in yeast prion formation in the cytoplasm. Ma
and Lindquist (1999) did not report whether mouse PrPScªseedsº the newly synthesized normal cellular form of
the protein then undergoes prion conversion leading to formation in yeast was Hsp104-dependent so it remains
to be established whether PrPSc formation does requireaggregate formation and the apparent dominant genetic
trait. one or more ªmolecular chaperones.º
Caution must therefore be taken in directly extrapolat-The identity and the prion-like behavior of the prion
determinants in question have been rigorously estab- ing from findings with yeast prions. Nevertheless, a se-
ries of new papers on yeast prions has now providedlished; [PSI1] is associated with Sup35p (otherwise
known as eRF3), an essential component of the transla- important clues to two of the major problems of prion
biology: what features of a prion protein make it behavetion termination machinery, while [URE3] is associated
with Ure2p, a protein that acts as a negative regulator of as such, and what prevents efficient interspecies trans-
fer of these novel cytoplasmically located ªinfectiousnitrogen metabolism. That neither protein shows amino
acid identity between one another or with mammalian agentsº?
Sup35p and Ure2p Have Prion-Forming DomainsPrP immediately raises the question: What sequence
and/or structural features of a prion protein make it that Are Both Modular and Transferable
The replication of yeast prions occurs by a protein-onlybehave as such? Recent studies on the two yeast prions
have begun to provide some answers. mechanism. Studies in vivo and in vitro show that the
N-terminal regions of both Sup35p and Ure2p are neces-A detailed overview of the evidence supporting Wick-
ner's proposal that Sup35p and Ure2p are prions can sary for the formation of their respective prion states,
although sequences in the C terminus of Ure2p may alsobe found in a review by Wickner and Chernoff (1999).
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Figure 1. The N-terminally Located Prion-
Forming Domains (PrD) of Sup35p and Ure2p
of Saccharomyces cerevisiae Contain a Num-
ber of Important Sequence Features
contribute to the prion behavior of Ure2p (Maddelein and partial) copies of an oligopeptide repeat that bears strik-
ing resemblance to the octapeptide repeat (the ªoctare-Wickner, 1999). In both proteins the N-terminally located
prion-forming domain (PrD) is not essential for protein peatº) of mammalian PrP (Figure 1). Amino acid substitu-
tion within one of the Sup35p-PrD repeats, or changesfunction per se, nor do the two PrDs share significant
amino acid sequence identity. What the two PrDs do in the numbers of copies of these repeats, can have
dramatic effects on both the [PSI1] phenotype in vivoshare, however, is an atypically high proportion of Gln
and Asn residues (.40%, Figure 1 and Table 1), two and on the seeded aggregation of Sup35p in vitro. For
example, a Gly58 to Asp58 substitution within repeatpolar amino acids with uncharged R groups, and an
overall low charge content. number 2 (R2) results in a dominant ªPsi-No-Moreº
(PNM) phenotype (Doel et al., 1994) while deletions en-The Sup35p- and Ure2p-PrDs are both modular and
transferable as fusion of either with the green fluores- compassing repeats R1±R3 (Ter-Avanesyan et al., 1994)
or R2±R5 (Liu and Lindquist, 1999) give a similar PNMcent protein (GFP) leads to the formation of discrete GFP
foci in cells carrying the prion form of the corresponding phenotype.
An indication that the R2 repeat may play a key role inprotein or PrD (Wickner and Chernoff, 1999). A striking
demonstration of the transferability of the Sup35p-PrD prion conversion has come from studying a constructed
mutant of Sup35p that contains two additional copieshas come from the work of Li and Lindquist (2000) who
constructed a recombinant version of the rat glucocorti- of the R2 repeat (R2E2). Liu and Lindquist (1999) found
that a [psi2] R2E2 mutant spontaneously reverted tocoid receptor fused to the Sup35p-PrD. The resulting
fusion protein, when expressed in yeast, was found to [PSI1] at a frequency some 5000-fold higher than the
wild-type [psi2] strain (i.e., a Sup35p-PrD containingexist in distinct stable and heritable functional states,
maintaining the epigenetic characteristics of Sup35p. seven rather than five oligopeptide repeats has a [PSI1]
ªmutatorº phenotype). These authors further showedThe resulting phenotypic changes (in transcription of a
glucocorticoid-regulated promoter driving expression of that the number of copies of the repeat within the
Sup35p-PrD also influenced the kinetics of Sup35p fiberthe E.coli lacZ gene) reflected changes in glucocorticoid
receptor function, but not Sup35p function. It remains formation in vitro in a manner that parallels its in vivo
behavior. Thus, both the number of oligopeptide repeatsto be established whether yeast prion PrDs can be used
to engineer such a novel means of regulating ªloss of and the amino acid composition of at least one of these
repeats in the Sup35p-PrD are important for the self-functionº to all types of proteins. The modular and trans-
ferable properties of yeast PrDs also has important evo- perpetuating change associated with the prion-like in-
heritance of the [PSI1]determinant.lutionary implications.
The Role of the Yeast PrD in Prion Conversion Mammalian PrP contains five complete copies of the
octarepeat PHGGGWGQ at its N terminus, and expan-One of the most tantalizing sequence features of the
Sup35p-PrD is the presence of five complete (and one sion in the number of octarepeats has been associated
Table 1. Yeast Proteins Showing Prion-like Behavior
PrD
Gene ORF PrD %Q1N GFP Foci Hsp104 Agn
SUP35 YDR172W aa 1±123 43 Yes Yes Yes
URE2 YNL229C aa 1±89 47 Yes ND Yes
RNQ1 YCL028W aa 153±405 43 Yes Yes Yes
NEW1 YPL226W aa 1±153 26 ND ND Yes
The data for RNQ1 are from Sondheimer and Lindquist (2000) and for NEW1 from Santoso et al. (2000). Two other proteins, YBR016W (a
hypothetical ORF) and Hrp1p (YOL123W) generate GFP foci when fused to GFP (Sondheimer and Lindquist, 2000). A yeast protein has, on
average, 9% Gln1Asn residues (Santoso et al., 2000). ND, not determined; PrD, prion-forming domain; Agn, ability to form high mol. wt.
aggregates in vivo; Hsp104, maintenance of the aggregated state is dependent upon Hsp104.
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with certain mammalian prion diseases. Charles Weiss- species. This cannot be an absolute barrier as the ap-
pearance of BSE-derived new variant CJD in humansmann and his colleagues (Weissmann et al., 1999) have,
however, reported that transgenic mice carrying a PrP stands testimony to. Nonetheless, numerous transgenic
studies in mice have shown that the PrP gene itselfallele lacking the N-terminal region encompassing the
octarepeats are still susceptible to scrapie infection, governs the species barrier, although the requirement
for a homologous PrP:cofactor interaction has not beenalthough the resulting neurodegenerative disease re-
quires a longer than usual incubation period and has a ruled out as a contributing factor. Recent efforts have
therefore been made to probe the molecular basis ofmuch lower level of infectivity. The nonessentiality of
the mammalian PrP octarepeats in prion conversion the species barrier using yeast prions.
While it is highly improbable that S. cerevisiae is eversuggests that other more general features of a prion
protein may be equally important. This must also be true ªinfectedº by a prion from another yeast species, it is
relatively straightforward to experimentally introduce afor prion formation in yeast not least because the Ure2p-
PrD has no oligopeptide repeats yet is able to efficiently heterologous yeast prion gene into S. cerevisiae to study
the consequences. This is exactly what three differentdirect prion formation in vivo and to form amyloid-like
fibers in vitro (Taylor et al., 1999; Thual et al., 1999). groups have now done (Chernoff et al., 2000; Kushnirov
et al., 2000; Santoso et al., 2000) and all have come toThe oligopeptide repeats in the Sup35p-PrD are not
the sole determinants that confer prion-like behavior to the same conclusion, namely that S. cerevisiae does
show a species barrier to Sup35p prion replication. AsSup35p. De Pace et al. (1998) have identified PNM alleles
of Sup35p that contain single amino acid substitutions with the mammalian prion species barrier, continued
propagation of the heterologous prion requires the pres-in a region particularly rich in Gln and Asn residues
(amino acids 8±33, Figure 1) which lies outside the region ence of the corresponding heterologous prion gene. In
these studies, the PrD domain of Sup35p from a range ofcarrying the oligopeptide repeats. Their findings suggest
that the high density of these two residues in the PrD is evolutionarily diverged yeast species including Candida
albicans (CaSup35p), Pichia methanolica (PmSup35p),a major contributor to the prion-like behavior of Sup35p.
This is further supported by Maddelein and Wickner and Kuyveromyces lactis (KlSup35p) was fused to either
the functional C domain of the S. cerevisiae Sup35p(1999), who showed that deletion of poly-Asn tracts in
the Ure2p-PrD impair [URE3] formation. Such localized (ScSup35p) or to GFP. The data obtained unequivocally
demonstrate that it is the PrD that confers the highhigh densities of Gln residues also increase the effi-
ciency of amyloid formation both in vivo and in vitro. degree of specificity to prion polymerization both in vivo
and in vitro.The poly-Gln expansions in the huntingtin protein, asso-
ciated with Huntington's Disease, is a particularly strik- Particularly enlightening have been the studies with
the CaSup35p-PrD fusions (Santoso et al., 2000). Theing example, although there is no evidence that the
huntingtin amyloid is infectious while the infectious PrPSc CaSup35p-PrD-ScSup35p fusion, when expressed at
low levels under the control of the ScSUP35 gene pro-is rich in neither Gln or Asn.
Are All Gln1Asn-Rich Yeast Proteins Prions? moter, remained soluble in a [PSI1] strain demonstrating
that the heterologous CaSup35p-PrD could not becomeSup35p and Ure2p are not the only Gln1Asn-rich pro-
teins in the yeast proteome. Surveys by Sondheimer and incorporated into the endogenous ScSup35p prion ag-
gregate when expressed at low levels. However, whenLindquist (2000) and Santoso et al. (2000) have revealed
several proteins with Gln-Asn-rich domains that behave a CaSup35p-PrD-GFP fusion was expressed at high lev-
els, prion-like foci formed in both [PSI1] and [psi2] cellslike the Sup35p- and Ure2p-PrDs in vivo (Table 1). The
most thorough analysis was undertaken on Rnq1p, with similar kinetics. Thus, the heterologous CaSup35p-
PrD can direct prion formation when overexpressed, butwhich satisfied all of the in vivo criteria used to diagnose
the Sup35p-PrD: modular, transferable to GFP, Hsp104- its polymerization is not influenced by the endogenous
prion. Neither are the heterologous CaSup35p-PrD-con-dependent aggregation, and inherited in a non-Mende-
lian fashion (Sondheimer and Lindquist, 2000). The strik- taining aggregates able to seed the polymerization of
soluble ScSup35p in the [psi2] strain, i.e., the two prionsing difference between the Sup35p- and Rnq1p-PrDs is
that the Rnq1p-PrD is C-terminally located: the region replicate independently in the same cell. The homolo-
gous Rnq1p prion also appears to replicate indepen-aa 153±405 is able to substitute for the Sup35p-PrD fully
recapitulating the phenotypic and epigenetic behavior dently of Sup35p (Sondheimer and Lindquist, 2000).
Using a clever two-plasmid-based assay, Santoso etof [PSI1]. It is therefore not essential that a yeast PrD
is N-terminally located. al. (2000) were also able to demonstrate that the heterol-
ogous CaSup35p-PrD can support prion-based inheri-Another striking feature of the Rnq1p ªprionº is that
it can be present in yeast laboratory strains in one of at tance and that a barrier prevents cross-seeding between
PrDs from different yeast species. However, Chernoffleast three distinct states of aggregation as defined by
ultracentrifugation (Sondheimer and Lindquist, 2000). It et al. (2000) have reported that over expression of
full-length PmSup35p can induce the prion form ofremains to be seen whether Rnq1p shows seeded in
vitro polymerization into amyloid-like fibers, but it can ScSup35p, albeit inefficiently, suggesting that the spe-
cies barrier can be by-passed with high-level overex-be considered a third yeast prion in spite of the fact that
there appears to be no phenotypic consequence to the pression of the heterologous PrD.
The specificity imparted by the PrD appears to beloss-of-function prion switch.
Yeast PrDs and the Species Barrier controlled by the Gln1Asn-rich region at the N terminus
of ScSup35p. By replacing the corresponding sequenceOne aspect of prion biology that is receiving consider-
able attention is the so-called ªspecies barrier,º i.e., the in the CaSup35p-PrD with amino acids 8±26 from the
ScSup35p (see Figure 1), Santoso et al. (2000) showedinability of a prion from one species to infect a different
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Liu, J.-J., and Lindquist, S. (1999). Nature 400, 573±576.that this chimeric PrD now behaves as the wild-type
Ma, J., and Lindquist, S. (1999). Nat. Cell Biol. 1, 358±361.ScSup35p. This result implies that this 19±amino acid
Maddelein, M.-L., and Wickner, R.B. (1999). Mol. Cell. Biol. 19, 4516±sequence is sufficient to confer species specificity to
4524.Sup35p polymerization and thus defines this region,
Prusiner, S.B., ed. (1999). Prion Biology and Diseases (Cold Springwhich lies outside the oligopeptide repeat±containing
Harbor, NY: Cold Spring Harbor Laboratory Press).region, as a major determinant of the ªspecies barrierº
Santoso, A., Chien, P., Osherovich, L.Z., and Weissman, J.S. (2000).in yeast.
Cell 100, 277±288.What now remains to be established is the mechanism
Sondheimer, N., and Lindquist, S. (2000). Mol. Cell 5, 163±172.underlying the species barrier to yeast prion propaga-
Taylor, K.L., Cheng, N., Williams, R.W., Stevens, A.C., and Wickner,tion. It might simply be at the level of PrD:PrD interac-
R.B. (1999). Science 283, 1339±1343.tions during polymerization. We know from studies with
Ter-Avanesyan, M.D., Dagkesamanskaya, A.R., Kushnirov, V.V., andthe PNM alleles of Sup35p that single amino acid
Smirnov, V.N. (1994). Genetics 137, 671±676.changes in the PrD can inhibit prion replication in yeast.
Thual, C., Komar, A.A., Bousset, L., Fernandez-Bellot, E., Cullin, C.,These findings might also be explained if this region of
and Melki, R. (1999). J. Biol. Chem. 274, 13666±13574.
the PrD were the binding site for a ªhelperº molecule.
Weissmann, C., Raeber, A.J., Shmerling, D., Aguzzi, A., and Manson,The obvious candidate would be Hsp104, although there
J.C. (1999). In Prion Biology and Diseases, S.B. Prusiner, ed. (Cold
is no evidence that a stable Hsp104:Sup35p interaction Spring Harbor, NY: Cold Spring Harbor Laboratory Press), pp.
occurs in vivo. An important transient interaction can 273±306.
not be ruled out (Wickner and Chernoff, 1999). Alterna- Wickner, R.B., and Chernoff, Y.O. (1999). In Prion Biology and Dis-
tively, it may be part of the binding site for some other eases, S.B. Prusiner, ed. (Cold Spring Harbor, NY: Cold Spring Har-
bor Laboratory Press), pp. 229±272.cellular protein involved in yeast prion propagation; for
example, the cytoskeletal assembly protein Sla1p stably Wickner, R.B. (1994). Science 264, 566±569.
interacts with the ScSup35p-PrD and influences [PSI1]
maintenance (Ballieul et al., 1999).
Conclusion
We have learned much about prion biology through the
study of yeast prions and their associated PrDs, but
caution must be exercised in extrapolating these find-
ings directly to mammalian prion behavior. It must not
be forgotten that mammalian PrPSc is an infectious agent
that can spread from cell to cell while there is no evi-
dence of cell-to-cell transmission of yeast prions other
than through cytoplasmic mixing. This apparent lack
of infectivity of yeast prions may simply reflect their
cytoplasmic location. Nevertheless, the recently pub-
lished studies have added significantly to our under-
standing of the molecular basis of yeast prion conver-
sion and maintenance. We now know the key sequence
features of a yeast PrD that drive prion conversion, and
the new data are consistent with a highly specific PrD±
PrD interaction mediating polymerization both in vivo
and in vitro. For both Sup35p and Ure2p the in vitro±
formed polymers are clearly amyloid-like, but we must
now determine whether Sup35p, Ure2p, and other yeast
prions are present in cells in the same form. This, to-
gether with an understanding of the underlying protein
structural framework, will allow us to build mechanistic
models for prion conversion in yeast.
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